相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Professor Alexandre Chan has been appointed Director of Cancer Survivorship and Wellness at the National Cancer Centre Singapore (NCCS). - Prof Chan joins NCCS from the University of California Irvine, where he served as founding Chair of the Department of Clinical Pharmacy Practice. - As President of the Multinational Association of Supportive Care in Cancer (MASCC), Prof Chan brings expertise in supportive care, survivorship, and integrative oncology. - He will lead NCCS's growth in clinical, research, and educational excellence across survivorship, integrative oncology, and rehabilitation.
- ImPact Biotech reported that 66% of patients with unresectable locally advanced pancreatic ductal adenocarcinoma became eligible for surgery following treatment with Padeliporfin VTP at the lowest light dose in a Phase 1 trial. - The vascular targeted photodynamic therapy demonstrated a well-tolerated safety profile with no complications related to arterial injury, thrombosis, or other VTP-related morbidity in the initial cohort. - The company is pursuing strategic partnerships for its low-grade upper tract urothelial carcinoma program while advancing the pancreatic cancer indication, which represents a large market opportunity with potential for accelerated regulatory pathway. - Topline data from the Phase 3 ENLIGHTED trial in UTUC and NDA submission are expected in 2026, with additional LA-PDAC Phase 1 results anticipated throughout the year.
- Elevated lipoprotein(a) affects approximately 20% of adults and is primarily genetically determined, serving as a significant risk marker for atherosclerotic cardiovascular disease, aortic stenosis, heart failure, and atrial fibrillation. - Early identification of cardiovascular risk factors like Lp(a) is crucial for preventing disease progression, reducing healthcare costs, and improving patient outcomes and quality of life. - While Lp(a) testing is generally well-covered by insurance, it is not typically considered a preventative service like traditional lipid panels, potentially resulting in cost-sharing for patients on commercial health plans.
• A groundbreaking analysis reveals that underrepresentation of women, minorities, and older adults in clinical trials for diabetes, heart disease, and hypertension has resulted in an estimated $11 trillion economic impact. • The National Academies of Sciences, Engineering, and Medicine (NASEM) report identifies systemic barriers across research institutions, IRBs, medical journals, and funding bodies that contribute to exclusion of diverse populations. • Dr. Jonathan Watanabe proposes comprehensive reforms including standardized trial inclusion criteria, improved NIH funding allocation, and enhanced compensation policies for study participants to address representation gaps.
